Table 4.
Risk factors for LVSI in high-grade serous ovarian carcinoma
| Univariate | Multivariate* | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| No. | LVSI (%) | OR (95%CI) | P-value | OR (95%CI) | P-value | |
| Age | 0.002 | 0.007 | ||||
| < 70 | 90 | 90.0% | 1 | 1 | ||
| ≥ 70 | 31 | 64.5% | 0.20 (0.07-0.55) | 0.19 (0.06-0.63) | ||
|
| ||||||
| Race | 0.57 | |||||
| Non-White | 19 | 78.9% | 1 | |||
| White | 102 | 84.3% | 1.43 (0.42-4.88) | |||
|
| ||||||
| CA125 | 0.20 | |||||
| <35 | 2 | 50% | 1 | |||
| ≥35 | 60 | 86.7% | 6.50 (0.37-114) | |||
|
| ||||||
| Stage | 0.002 | 0.006 | ||||
| I and II | 6 | 16.7% | 1 | 1 | ||
| III and IV | 115 | 87.0% | 33.3 (3.64-305) | 38.7 (3.40-439) | ||
|
| ||||||
| Cytoreduction | 0.08 | |||||
| Sub-optimal | 71 | 88.7% | 1 | |||
| Optimal | 50 | 76.0% | 0.40 (0.15-1.07) | |||
|
| ||||||
| p53 | 0.81 | |||||
| No | 34 | 85.3% | 1 | |||
| Yes | 85 | 83.5% | 0.87 (0.29-2.65) | |||
|
| ||||||
| MDR1 | 0.83 | |||||
| No | 96 | 85.4% | 1 | |||
| Yes | 16 | 87.5% | 1.20 (0.25-5.84) | |||
|
| ||||||
| EGFR | 0.91 | |||||
| No | 48 | 83.3% | 1 | |||
| Yes | 63 | 82.5% | 0.95 (0.35-2.57) | |||
|
| ||||||
| HER2 | 0.55 | |||||
| No | 88 | 83.0% | 1 | |||
| Yes | 32 | 87.5% | 1.44 (0.44-4.71) | |||
|
| ||||||
| ER | 0.002 | 0.039 | ||||
| No | 15 | 53.3% | 1 | 1 | ||
| Yes | 98 | 87.8% | 6.27 (1.93-20.4) | 4.48 (1.08-18.6) | ||
|
| ||||||
| PR | 1.0 | |||||
| No | 102 | 81.4% | 1 | |||
| Yes | 10 | 100% | na | |||
|
| ||||||
| DNA anuploid | 0.42 | |||||
| No | 19 | 89.5% | 1 | |||
| Yes | 99 | 81.8% | 0.53 (0.11-2.50) | |||
|
| ||||||
| S-phase fraction | 0.95 | |||||
| <11% | 70 | 82.9% | 1 | |||
| ≥11% | 48 | 83.3% | 1.03 (0.39-2.76) | |||
P-values for binary logistic regression test.
*
multivariate analysis with conditional backward method. Abbreviations: No., number of cases; LVSI, lymphovascular space invasion; OR, odds ratio; 95%CI, 95% confidence interval; MDR1, multi-drug resistance 1; EGFR, epidermal growth factor receptor, HER2, human epidermal growth factor receptor 2; ER, estrogen receptor alpha; and PR, progesterone receptor; na not available.